Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

NCT06657391 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

396

Enrollment

OTHER

Sponsor class

Conditions

Transfusion Dependent Thalassemia

Interventions

DRUG: recombinant humanized anti-CD25 monoclonal antibody

Sponsor

Rongrong Liu